![]() |
![]() |
![]() |
![]() |
P02-01 | Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy. | David J. Pinato | ![]() |
![]() |
|||
P07-01 | Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome | Johann von Felden | ![]() |
![]() |
|||
P03-01 | Tumor Burden Score: a useful tool to predict immune-related hepatotoxicity during immunotherapy in HCC | Antonio DAlessio | ![]() |
![]() |
|||
P06-01 | Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization | Filippo Pelizzaro | ![]() |
![]() |
|||
P01-01 | Clinical Strategy of Diagnosing patients with Hepatocellular Carcinoma based on Latent Transforming Growth Factor-Beta Binding Protein 1 | Mohamed Abdel-Samiee | ![]() |
![]() |
|||
P04-01 | Application of BCLC-B subclassification and the Hong Kong Liver Cancer Systems to Intermediate Stage Hepatocellular Carcinoma | Coskun Ozer Demirtas | ![]() |
![]() |
|||
P05-01 | Hepatocellular Carcinoma in Non-Cirrhotic Liver Arises in a More Advanced Tumoral Appearance | Coskun Ozer Demirtas | ![]() |
![]() |
|||
P04-02 | Curative versus palliative treatments for recurrent hepatocellular carcinoma: an italian nationwide study | Francesca Carissimi | ![]() |
![]() |
|||
P03-02 | PIVKA-II is a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals | Elisabetta Degasperi | ![]() |
![]() |
|||
P06-02 | Metabolic rewiring in tumoral primary cholangiocytes: perspective for target therapy | Michela Anna Polidoro | ![]() |
![]() |
|||
P02-02 | Response rates to direct antiviral agents (DAA) among hepatitis C virus infected patients who develop hepatocellular carcinoma following DAA treatment | Alessandro Croce | ![]() |
![]() |
|||
P05-02 | Global characterisation of tumor infiltrate of Intrahepatic Cholangiocarcinoma by Sigle-Cell Sequencing | Ana Lleo | ![]() |
![]() |
|||
P07-02 | High rate of HBV S-integrated human ESPL1 fusion gene is detected in HBV-related liver cancer patients: A Chinese case-control study | Rongming Wang | ![]() |
![]() |
|||
OP01-02 | Deleting in vivo beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or mesenchymal hepatoblastoma similaryto Apc loss-of-function | Daniel Zaldumbide | ![]() |
![]() |
|||
P01-02 | Radiological and pathological characteristics associated with aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation | marianne ziol | ![]() |
![]() |
|||
P07-03 | urinary epidermal growth factor-related transforming growth factors and serum alpha-fetoprotein as tumor markers of hepatocellular carcinoma | Jung-Fa Tsai | ![]() |
![]() |
|||
P02-03 | Hepatotoxicity during treatment with immune checkpoint inhibitors: what happens to the liver with tumor infiltration? | DAlessio Antonio | ![]() |
![]() |
|||
P04-03 | Association of single nucleotide polymorphisms for PNPLA3, Notch3 and EGF with hepatocellular carcinoma in alcohol-related liver disease | Anna Mrzljak | ![]() |
![]() |
|||
P01-03 | Hepatocellular Carcinoma: Most common presentation and its association with Portal vein thrombosis in different age groups | Muhammad Arsalan | ![]() |
![]() |
|||
P03-03 | External Validation of the Toronto Hepatocellular Carcinoma Risk Index in Turkish Cirrhotic Patients | Coskun Ozer Demirtas | ![]() |
![]() |
|||
P05-03 | Filamin-A expression predicts recurrence of mass-forming cholangiocarcinoma after hepatectomy | Flavio Milana | ![]() |
![]() |
|||
P06-03 | Circulating mir-4454 as a predictor of therapy response and disease-free survival in hepatocellular carcinoma | Muhammad Yogi Pratama | ![]() |
![]() |
|||
P03-04 | Deletion of erk5 protein kinase in myeloid cells impairs liver regeneration in mice | Giovanni Di Maira | ![]() |
![]() |
|||
P07-04 | Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinomas | nathalie guedj | ![]() |
![]() |
|||
P01-04 | randomized, open label, perioperative phase 2 study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable hcc | Ahmed Kaseb | ![]() |
![]() |
|||
P02-04 | Epidemiological trends of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease in Italy. On behalf of the ITA.LI.CA. study group | Alessandro Vitale | ![]() |
![]() |
|||
P06-04 | Characterization of novel oncogenic and tumor suppressor circRNAs in hepatocellular carcinoma | Rok Razpotnik | ![]() |
![]() |
|||
P05-04 | In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine | Tudor Mocan | ![]() |
![]() |
|||
P04-04 | DKK1 drives cholangiocarcinoma growth through modulation of the immune microenvironment | Ed Jarman | ![]() |
![]() |
|||
P03-05 | cfDNA in Hepatocellular Carcinoma | Ksenia Ellum | ![]() |
![]() |
|||
P06-05 | Prognostic role of a new index (PECS index) in advanced biliary tract cancer patients treated with first line chemotherapy: Training and Validation cohorts. | Giulia Rovesti | ![]() |
![]() |
|||
P07-05 | Clinical significance of serum albumin functional parameters for diagnosis of hepatocellular carcinoma | Rinat Gimadiev | ![]() |
![]() |
|||
P05-05 | New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma | Anne Olbrich | ![]() |
![]() |
|||
P04-05 | Telomerase reverse transcriptase mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish patients with hepatocellular carcinoma | Stine Karlsen | ![]() |
![]() |
|||
P01-05 | Prognostication of hepatocellular carcinoma under Sorafenib: external validation of the PROSASH-II model | Vito Sansone | ![]() |
![]() |
|||
P02-05 | Immunological approach to identify predictive factors for development of hepatocellular carcinoma in patients treated with direct-acting antivirals | Zuzana MACEK JILKOVA | ![]() |
![]() |
|||
P03-06 | The impact of postoperative ascites on survival after hepatectomy for hepatocellular carcinoma: A multicentric nation-based analysis | Simone Famularo | ![]() |
![]() |
|||
P06-06 | Hepatic lesion involvig the inferior vena cava: surgical management. | Pio Corleone | ![]() |
![]() |
|||
P02-06 | Interplay of PNPLA3 and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients | Carla De Benedittis | ![]() |
![]() |
|||
P01-06 | Natural history of hepatobiliary hypointense-only found at magnetic resonance imaging with Gd-EOB-DTPA in cirrhotic patients: time-dependent effects of dimensional increase and diffusion weighted imaging alterations | Francesca Benevento | ![]() |
![]() |
|||
P05-06 | Distinct mechanisms are responsible for the activation of the NRF2-KEAP1 pathway at different steps of hepatocarcinogenesis | Amedeo Columbano | ![]() |
![]() |
|||
P07-06 | Salvage AALDLT for HCC beyond all criteria yield equivilant results to Milan criteria in high prevalence young HCC patients country. | Manar Salah | ![]() |
![]() |
|||
P04-06 | Clinical outcome of lenvatinib therapy in Japanese patients with unresectable hepatocellular carcinoma a nationwide multicenter study | Kaoru Tsuchiya | ![]() |
![]() |
|||
P01-07 | The concept of time-varying therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. On behalf of the ITA.LI.CA. study group. | Alessandro Vitale | ![]() |
![]() |
|||
P03-07 | Biochemical and Clinical Evidence of Hepatocellular Carcinoma among Poorly Viral Suppressed ART Initiators in Southwestern Nigeria | Ayodeji Faremi | ![]() |
![]() |
|||
P04-07 | Umbelliferone loaded Nano-Lipidic Carrier exerts Diethylnitrosamine induced Hepatic Cancer via Attenuation of cellular inflammation and cell proliferation | efl2yjk6bo efl2yjk6bo | ![]() |
![]() |
|||
P06-07 | Multicenter validation of a scoring system to predict survival in biliary tract cancers receiving second-line chemotherapy | Massimiliano Salati | ![]() |
![]() |
|||
P02-07 | The NADPH oxidase NOX4 regulates lipid metabolism, which contributes to its tumor suppressor actions in hepatocellular carcinoma | Isabel Fabregat | ![]() |
![]() |
|||
P05-07 | Prognostic role of blood eosinophil count in sorafenib-treated hepatocellular carcinoma patients: time to reconsider the minorities | Giorgia Marisi | ![]() |
![]() |
|||
P07-07 | Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. | David Pinato | ![]() |
![]() |
|||
P03-08 | Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (tNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC). | David Pinato | ![]() |
![]() |
|||
P04-08 | Stereotactic ablative radiotherapy in the management of metastatic and recurrent biliary tract cancer: single institution analysis of outcome and toxicity. | Ciro Franzese | ![]() |
![]() |
|||
P06-08 | The Six and Twelve score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
P02-08 | Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care | Massimo Iavarone | ![]() |
![]() |
|||
P05-08 | Prevalence and impact of sarcopenia in patients undergoing liver transplantation for hepatocellular carcinoma | Ana Ostojic | ![]() |
![]() |
|||
P07-08 | Possible hepatoprotective effect of chlorogenic acid and protocatechuic acid combinational approach against diethylnitrosamine induced hepatocarcinogenesis in rodents as a multitargeted ligand | Ekta Yadav | ![]() |
![]() |
|||
P01-08 | Galactose Conjugated PPI Dendrimers for Liver targetting | Mani Bhargava | ![]() |
![]() |
|||
P05-09 | Dissecting a novel strategy to target Mitochondria in Bile Duct Cancers | Carotenuto Pietro | ![]() |
![]() |
|||
P04-09 | TREM2 protects the liver against hepatocellular carcinoma through multifactorial protective mechanisms | Ibone Labiano | ![]() |
![]() |
|||
P07-09 | Patient-led functional genomics identifies novel drivers of intrahepatic cholangiocarcinoma | Nicholas Younger | ![]() |
![]() |
|||
P02-09 | Nonalcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study | Stefania De Lorenzo | ![]() |
![]() |
|||
P01-09 | Major impact of personalised dosimetry using 90Y loaded glass microspheres SIRT in HCC: final Overal Survival analysis of a multicentre randomized phase II study. | Etienne Garin | ![]() |
![]() |
|||
P06-09 | Role of transient elastography in early detection of hepatocellular carcinoma in cirrhotic patients. | Abdel Ghani Badran | ![]() |
![]() |
|||
P03-09 | Developing high drug-load arsenic trioxide microsphere for chemoembolization of hepatocellular carcinoma | Gong Feng | ![]() |
![]() |
|||
P07-10 | NK-cell dysfunction in Hepatocellular Carcinoma: modulatory approches for functional restoration | Alessandra Zecca | ![]() |
![]() |
|||
P05-10 | Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single center experience | Federica Invernizzi | ![]() |
![]() |
|||
P04-10 | Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a mirror of the tumor features | Ainhoa Lapitz | ![]() |
![]() |
|||
P06-10 | Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years | Enrico Galmozzi | ![]() |
![]() |
|||
P02-10 | Albumin to gamma-glutamyltransferase and platelet to lymphocyte ratio do not predict recurrence and recurrence-free- survival after complete response to first-line HCC treatment | Alberta De Monti | ![]() |
![]() |
|||
P01-10 | Liquid Crystalline Nanoparticles based delivery of an Anticancer bioactive | Saurabh Bhargava | ![]() |
![]() |
|||
P03-10 | Evolution of indications for liver transplantation in the last 15 years: a single center experience in Madrid | Christie Perello | ![]() |
![]() |
|||
P03-11 | Pilot study of transarterial radioembolization with Yttrium-90 in patients with hepatocellular carcinoma | Pablo Florez-Díez | ![]() |
![]() |
|||
P07-11 | Safety Comparison between Drug-eluting Beads and Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicentre Study | Lei Zhang | ![]() |
![]() |
|||
P04-11 | Does tumor size matter in intrahepatic cholangiocarcinoma? a population-based analysis | Xianwei Yang | ![]() |
![]() |
|||
P02-11 | A Retrospective Analysis of the Course of LI-RADS 3-4 Hepatic Lesions | Panita Mettikanont | ![]() |
![]() |
|||
P01-11 | Mitochondriotropic Carbon nanotubes for efficient Tumor Targetting | Varun Bhargava | ![]() |
![]() |
|||
P05-11 | Autoimmunity associated with primary biliray cholangitis prevents the development of cholangiocarcinoma in mouse models | Juliette Paillet | ![]() |
![]() |
|||
P06-11 | Circulating Small-RNA signature evidenced a susceptibility to HCC occurence in DAA-treated patients | Devis Pascut | ![]() |
![]() |
|||
P01-12 | Hepatic Uptake Index in the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging estimates functional liver reserve and predicts post-hepatectomy liver failure | Bruno Branciforte | ![]() |
![]() |
|||
P07-12 | The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma | Johann von Felden | ![]() |
![]() |
|||
P03-12 | Alpha Feta-Protein use as a standalone screening tool for hepatocellular carcinoma: single centre experience | Clare Foley | ![]() |
![]() |
|||
P02-12 | Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology | Federica Invernizzi | ![]() |
![]() |
|||
P06-12 | Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC | Vito Sansone | ![]() |
![]() |
|||
P05-12 | Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma | Mirella Pastore | ![]() |
![]() |
|||
P04-12 | c-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development | jack leslie | ![]() |
![]() |
|||
P05-13 | Association between survival of patients with hepatocellular carcinoma and 18F-fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography | Kirstine Bak-Fredslund | ![]() |
![]() |
|||
P04-13 | Th therapeutic potential of adipose tissue-derived mesenchymal stem cells to enhance radiotherapy effects on hepatocellular carcinoma | Lingyun Wu | ![]() |
![]() |
|||
P01-13 | DNA damage response protein checkpoint kinase 2 (CHK2) links chromosomal instability to cellular metabolism in hepatocellular carcinoma (HCC) | Gianluca Bruno | ![]() |
![]() |
|||
P06-13 | Genetic risk factors of denovo hepatitis C-related hepatocellular carcinoma previously treated with direct acting antivirals | hend shousha | ![]() |
![]() |
|||
P07-13 | Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis | Alessandra Pivetti | ![]() |
![]() |
|||
P03-13 | Feasibility of ultrasound-guided percutaneous biopsy in peri-hilar focal biliary lesions of the liver: a case series | Roberto Gabbiadini | ![]() |
![]() |
|||
P02-13 | A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals | Elisabetta Degasperi | ![]() |
![]() |
|||
P01-14 | Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma | David Pinato | ![]() |
![]() |
|||
P07-14 | Characteristics of hepatocellular carcinoma post direct antiviral treatment of chronic hepatitis C patients : comparative study with non - direct - acting antivirals - treated patients | Mohamed Fathey Abdelkhalek Elgazzar | ![]() |
![]() |
|||
P02-14 | Programmed Cell Death-1 Gene Haplotypes are Associated with Hepatocellular Carcinoma | Coskun Ozer Demirtas | ![]() |
![]() |
|||
P04-14 | Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population | Monika Lewinska | ![]() |
![]() |
|||
P03-14 | Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition | CESAR GASPARI | ![]() |
![]() |
|||
P05-14 | Endothelial inducible T cell co-stimulator ligand (ICOSL) regulates adhesion molecule expression on liver endothelium: implications for senescence-mediated immune surveillance | Daniel Patten | ![]() |
![]() |
|||
P06-14 | Analysis of risk factors for survival and recurrence of hepatocellular carcinoma after liver transplantation | Petra Dinjar Kujundic | ![]() |
![]() |
|||
P03-15 | Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models | Daniel Geh | ![]() |
![]() |
|||
P06-15 | Radiological response to trans-arterial chemoembolisation (TACE) determines outcome in patients with hepatocellular carcinoma (HCC) | Nada Elamin | ![]() |
![]() |
|||
P01-15 | Prognostic significance of endocan and VEGF in the prediction of hepatocellular carcinoma in patients with compensated chronic viral hepatitis C-related cirrhosis | Jolanta Zuwala-Jagiello | ![]() |
![]() |
|||
P02-15 | Hepatocellular carcinoma in co-infected patients: more aggressive tumor behavior? | Lisa Rodrigues Da Cunha Saud | ![]() |
![]() |
|||
P07-15 | Common polymorphisms in the interleukin-1 beta gene are associated with HCV-related HCC in Caucasian patients | Janett Fischer | ![]() |
![]() |
|||
P05-15 | Activated platelets drive carcinogenesis and tumor growth in hepatocellular carcinoma | Natasa Pavlovic | ![]() |
![]() |
|||
P04-15 | Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of biliary tract cancer | Sven Loosen | ![]() |
![]() |
|||
P06-16 | miR-34a is activated in NAFLD and NASH-associated HCC, and correlates with key disease hallmarks | André Simão | ![]() |
![]() |
|||
P02-16 | A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab (D) or durvalumab plus bevacizumab (B) therapy in patients (Pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-1 | Humna Rizki | ![]() |
![]() |
|||
P07-16 | Incidence of indeterminate hepatic nodules in the preoperative magnetic resonance imaging in patients with colorectal cancer, their diagnosis, management and clinical outcome | Mizelle Dsilva | ![]() |
![]() |
|||
P03-16 | Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) | Leland Yee | ![]() |
![]() |
|||
P04-16 | Fatty acids regulate the biology of cholangiocarcinoma cells | Giulia Lori | ![]() |
![]() |
|||
P01-16 | Developing a bio-mimetic 3D model for hepatocellular carcinoma and the stromal micro-environment | Carlemi Calitz | ![]() |
![]() |
|||
P05-16 | Vascular invasion, portal vein thrombosis and dermatological events predict and prognosis the evolution and survival of patients with advanced hepatocellular carcinoma treated with sorafenib | Ioana Riaño | ![]() |
![]() |
|||
P02-17 | A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan | Huma Qureshi | ![]() |
![]() |
|||
P03-17 | E2F1 and E2F2 regulate glycerophospholipid metabolism in nonalcoholic fatty-liver disease-related hepatocarcinogenesis | Francisco Gonzalez-Romero | ![]() |
![]() |
|||
P06-17 | A novel significance of apurinic/apyrimidinic endonuclease/redox effector factor 1 protein in hepatic cancer stem cells | Caecilia Sukowati | ![]() |
![]() |
|||
P04-17 | Role of the tandem SOX17-MRP3 in the poor response of cholangiocarcinoma to chemotherapy | Elisa Lozano | ![]() |
![]() |
|||
P07-17 | Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 | Michela Ciruolo | ![]() |
![]() |
|||
P01-17 | Identification of a proteomic signature in advanced hepatocellular carcinoma predicting response to sorafenib | Frederic Saltel | ![]() |
![]() |
|||
P05-17 | Hepatotoxicity from immune-checkpoint inhibition in the treatment of hepatocellular carcinoma: outcomes and tissue biomarker analysis | Nicola Personeni | ![]() |
![]() |
|||
P05-18 | Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma | Ana Peleteiro Vigil | ![]() |
![]() |
|||
P04-18 | Comparison between stratification system for liver cancer BCLC and HKLC-5 as a predictor of mortality in a university hospital cohort in Chile | Rodrigo Wolff | ![]() |
![]() |
|||
P07-18 | Composite targeting of nuclear receptors protects mice from NAFLD progression towards HCC | Tawhidul Islam | ![]() |
![]() |
|||
P06-18 | Empowerment of liver cancer patients for an improved management of post-embolization syndrome: Impact of a Nurses Educational program | Neus Llarch | ![]() |
![]() |
|||
P01-18 | The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib | Claudia Campani | ![]() |
![]() |
|||
P02-18 | Regulation of the biology of cholangiocarcinoma (CCA) cells by extracellular-signal regulated kinase 5 (ERK5) | Giovanni Di Maira | ![]() |
![]() |
|||
P03-18 | Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis | Pietro Guerra | ![]() |
![]() |
|||
P05-19 | SCCA-IgM predicts prognosis differently according to gender in hepatocellular carcinoma patients treated with transarterial chemoembolization | Filippo Pelizzaro | ![]() |
![]() |
|||
P02-19 | A Blood-Based DNA Methylation Test for Early Detection of Hepatocellular Carcinoma | Dhruvajyoti Roy | ![]() |
![]() |
|||
P01-19 | Development of diet-induced NASH/HCC model in Sprague Dawley rats. | Lydie Carreres | ![]() |
![]() |
|||
P06-19 | SImBA: a user-friendly high throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines | Elias Van De Vijver | ![]() |
![]() |
|||
P03-19 | Inactivation of the BAP1 tumor suppressor defines a subgroup of hepatocellular carcinoma with fibrolamellar features | Theo Hirsch | ![]() |
![]() |
|||
P04-19 | Magnetic resonance of hepatocellular carcinoma treated with radiofrequency ablation: Radiomics to predict treatment response - preliminary results | Claudia Maccali | ![]() |
![]() |
|||
P07-19 | Variable expression of venous clot coordinator high mobility group box-1 in patients with hepatocellular carcinoma with or without portal vein thrombosis | Erica Matino | ![]() |
![]() |
|||
P03-20 | Targeting antiapoptotic proteins Bcl-xL and Mcl-1 in cholangiocarcinoma | Paula Katharina Morgane Hoffmeister | ![]() |
![]() |
|||
P04-20 | PARP-1 inhibition preferentially impairs KRAS-mutated intrahepatic cholangiocarcinoma and induces distinct molecular alterations | Friederike Mahn | ![]() |
![]() |
|||
P05-20 | Differential Role of TGF-Beta1&2 on Proliferative and Invasive Properties in Primary Liver Cancer | Sharon Pereira | ![]() |
![]() |
|||
P02-20 | miRNA profiling of biliary intraepithelial neoplasia reveals step-wise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis | Stephanie Roessler | ![]() |
![]() |
|||
P01-20 | Portal hypertension and sequential bilobar treatment increase risk of hepatic decompensation in patients with hepatocellular carcinoma treated with 90Yttrium radioembolization | Laura Carrion | ![]() |
![]() |
|||
P06-20 | Involvement of the glycan-binding protein galectin-1 in hepatocellular carcinoma cell drug resistance | María Fernanda Troncoso | ![]() |
![]() |
|||
P04-21 | Inhibitory effects of butyrate carrier structured lipids on persistent preneoplastic lesions induced by the resistant hepatocyte model of hepatocarcinogenesis | Juliana Marques Affonso | ![]() |
![]() |
|||
PB07-21 | SBRT vs TAE/TACE in Hepatocellular carcinoma: results from a Phase III trial (NTC02323360) | Tiziana Comito | ![]() |
![]() |
|||
P07-21 | Advances in serum biomarkers for primary and secondary liver carcinomas | Marie Karlikova | ![]() |
![]() |
|||
P03-21 | Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma | Luca Ielasi | ![]() |
![]() |
|||
P02-21 | plasma circulating cell-free DNA integrity is a risk factor of denovo hepatitis-C related hepatocellular carcinoma treated or not with direct acting antiviral therapy | hend shousha | ![]() |
![]() |
|||
P05-21 | Critical modifications of ganglioside patterns in human cholangiocarcinoma | Benedetta Piombanti | ![]() |
![]() |
|||
P01-21 | Targeting tumor-initiating cells as an effective approach to overcome sorafenib resistance in hepatocellular carcinoma | Darko Castven | ![]() |
![]() |
|||
P06-21 | Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic Hepatitis B and C patients | Stijn Van Hees | ![]() |
![]() |
|||
P05-22 | Applicability of Six and Twelve model in patients with hepatocellular carcinoma treated with DEB-TACE | Maria Pipa Muñiz | ![]() |
![]() |
|||
PB07-22 | Inhibiting endoplasmic reticulum stress in hepatic stellate cells decreases the progression of hepatocellular carcinoma | Natasa Pavlovic | ![]() |
![]() |
|||
P02-22 | The role of stereotactic body radiation therapy in the management of hepatocellular carcinoma: outcome and toxicity from a single institution experience. | Ciro Franzese | ![]() |
![]() |
|||
P06-22 | ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signalling between tumor cells and cancer-associated fibroblasts | Javier Vaquero | ![]() |
![]() |
|||
P01-22 | Characterisation of a plasmid-based mouse model of liver cancer with concomitant liver injury | Vincent Chiu | ![]() |
![]() |
|||
P04-22 | Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma | Michela Ciruolo | ![]() |
![]() |
|||
P03-22 | Impact of a Nurse Educational program for patients empowerment during sequential systemic therapy for hepatocellular carcinoma | Gemma Iserte Fort | ![]() |
![]() |
|||
PB04-23 | Specific RNA profiles in serum and urine extracellular vesicles of patients with cholangiocarcinoma mimicking tumor tissue and cell expression: a novel liquid biopsy approach | Ainhoa Lapitz | ![]() |
![]() |
|||
PB07-23 | Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial | Jennifer Humbert | ![]() |
![]() |
|||
PB05-23 | miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD | Pedro Miguel Rodrigues | ![]() |
![]() |
|||
P01-23 | The role of endosonography and endosonography guided fine needle aspiration in detection of small sized liver metastasis in patients with pancreatic and gastro-intestinal malignancy | Saeed M. El-Nahaas | ![]() |
![]() |
|||
P02-23 | Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology | Ewald Doornebal | ![]() |
![]() |
|||
PB03-23 | Neoangiogenic transcriptomic signature identifies HCCs with worse response to treatment: long-term results of a prospective study | Erica Villa | ![]() |
![]() |
|||
PB05-24 | Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation/carcinogenesis in non-alcoholic steatohepatitis | Marta B. Afonso | ![]() |
![]() |
|||
PB07-24 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab/placebo: results from two randomised phase 3 trials (REACH/REACH-2) | Peter Galle | ![]() |
![]() |
|||
PB03-24 | Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. | John Connell | ![]() |
![]() |
|||
PB04-24 | Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides | Julien Calderaro | ![]() |
![]() |
6-8 February 2020 Prague
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|